References
- Istituto Superiore di Sanità. Aggiornamento nazionale 20 maggio 2020-0re 16:00. Istituto Superiore di Sanità; 2020.
- Signorelli C, Scognamiglio T, Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomed. 2020;91:175–179.
- Lu X, Xiang Y, Du H, Wong GW-K. SARS-CoV-2 infection in children – understanding the immune responses and controlling the pandemic. Pediatr Allergy Immunol. doi:10.1111/pai.13267.
- Cron RQ, Chatham WW. The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic. J Rheumatol. 2020. doi:10.3899/jrheum.200492.
- Xia J, Tong J, Liu M, Shen Y, Guo D Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020. doi:10.1002/jmv.25725.
- Reviglio VE, Osaba M, Reviglio V, Chiaradia P, Kuo IC, O’Brien TP. COVID-19 and Ophthalmology: A New Chapter in an Old Story. Med Hypothesis Discov Innov Ophthalmol 2020;9:71–73.
- Lai THT, Tang EWH, Chau SKY, Fung KSC, Li KKW. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. Graefes Arch Clin Exp Ophthalmol. 2020;258:1049–1055.
- Borrelli E, Sacconi R, Querques L, et al. Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy. Eye. 2020;34(7):1175, 1176. doi:10.1038/s41433-020-0880-6.
- Linee Guida e Raccomandazioni SOI. Emergenza sanitaria da SARS-CoV-2. Riorganizzazione dell’attività assistenziale oculistica nella fase 2. Approvate dalla Società Oftalmologica Italiana −3 maggio 2020. Primo aggiornamento −10 maggio 2020.
- Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Annals of the Rheumatic Diseases. 2020;annrheumdis-2020-217615. doi:10.1136/annrheumdis-2020-217615.
- Costi S, Caporali R, Cimaz R. Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy. Pediatr Drugs. 2020;22(3):263–264. doi:10.1007/s40272-020-00395-2.
- Filocamo G, Minoia F, Carbogno S, Costi S, Romano M, Cimaz R. Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs. J Rheumatol. 2020;jrheum.200483. doi:10.3899/jrheum.200483.
- Licciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatr Rheumatol. 2020;18(1):35. doi:10.1186/s12969-020-00422-z.
- PReS – English: News Story. https://www.pres.eu/news/newsstory.html?id=29.
- Li J-PO, Lam DSC, Chen Y, Ting DSW, Li J-PO, Lam DSC, Chen Y, Ting DSW. Novel Coronavirus disease 2019 (COVID-19): the importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020;104(3):297–298. doi:10.1136/bjophthalmol-2020-315994.
- Sadhu S, Agrawal R, Pyare R, et al. COVID-19: limiting the Risks for Eye Care Professionals. Ophthalmol Ther. 2020;9(2):231–234. doi:10.1007/s40123-020-00251-z.
- Parravano M, Borrelli E, Costanzo E, Sacconi R, Varano M, Querques G. Protect Healthcare Workers and Patients from COVID-19: the Experience of Two Tertiary Ophthalmology Care Referral Centers in Italy. Ophthalmol Ther. 2020;9:231–234.